TB-500 Fragment Initiates Phase 1/2 Trial for Atherosclerotic Cardiovascular Disease Biomarkers
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
Key Findings
- Study is currently recruiting participants (NCT07487363)
- No findings on safety, tolerability, or efficacy have been reported yet
tb-500
thymosin beta 4
atherosclerotic cardiovascular disease
ascvd
endothelial dysfunction
phase 1/2 trial